Published in N Engl J Med on September 20, 2001
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol (2010) 9.28
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol (2014) 4.30
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation (2010) 2.71
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ (2004) 2.62
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Microalbuminuria in HIV infection. AIDS (2007) 2.28
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol (2005) 2.25
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors. Can Fam Physician (2004) 2.18
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2014) 2.16
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A (2008) 2.06
Biochemical effects of irbesartan in experimental diabetic nephropathy. Indian J Pharmacol (2009) 2.04
Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int (2012) 1.92
Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care (2012) 1.85
T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol (2010) 1.84
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol (2012) 1.75
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev (2010) 1.66
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia (2011) 1.53
The kidney in type 2 diabetes therapy. Rev Diabet Stud (2011) 1.50
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Diabetic nephropathy. Diabetol Metab Syndr (2009) 1.43
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 1.43
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res (2013) 1.42
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med (2016) 1.40
Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice. Mediators Inflamm (2016) 1.40
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study. BMC Nephrol (2017) 1.39
Prevalence and awareness of CKD among African Americans: the Jackson Heart Study. Am J Kidney Dis (2009) 1.37
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol (2008) 1.34
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care (2009) 1.33
Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant (2010) 1.32
Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med (2001) 1.30
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag (2008) 1.30
Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol (2009) 1.29
New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol (2010) 1.29
Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care (2011) 1.28
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol (2008) 1.24
Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag (2009) 1.22
Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA (2016) 1.19
Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol (2009) 1.19
Renal autoregulation in health and disease. Physiol Rev (2015) 1.18
Race and kidney disease: role of social and environmental factors. J Natl Med Assoc (2002) 1.18
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care (2011) 1.18
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis (2010) 1.13
Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes (2013) 1.11
Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol (2009) 1.09
Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy. J Investig Med (2013) 1.09
Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst (2010) 1.08
Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant (2008) 1.08
A critical review of mathematical models and data used in diabetology. Biomed Eng Online (2006) 1.08
Initial implementation of a web-based consultation process for patients with chronic kidney disease. Ann Fam Med (2013) 1.07
Chronic renal disease. BMJ (2002) 1.06
Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Intern Med (2004) 1.05
From design to implementation--the Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program. BMC Med Inform Decis Mak (2010) 1.05
Systems biology of kidney diseases. Kidney Int (2011) 1.05
Medical care costs associated with progression of diabetic nephropathy. Diabetes Care (2011) 1.03
Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002. J Gen Intern Med (2006) 1.03
Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis (2013) 1.02
B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. J Am Soc Nephrol (2015) 1.02
Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc (2002) 1.00
Progression and regression in renal vascular and glomerular fibrosis. Int J Exp Pathol (2004) 0.99
Kidney aging--inevitable or preventable? Nat Rev Nephrol (2011) 0.99
Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: a 12 years observational study. Indian J Med Res (2012) 0.99
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Microalbuminuria in diabetes mellitus. CMAJ (2002) 0.97
Nephrology: 4. Strategies for the care of adults with chronic kidney disease. CMAJ (2003) 0.97
Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia. Case Rep Transplant (2012) 0.96
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol (2011) 0.96
Recent advances in diabetic nephropathy. Postgrad Med J (2004) 0.96
Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol (2012) 0.96
Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol (2010) 0.95
Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS (2011) 0.95
Diabetic nephropathy: a disorder of oxygen metabolism? Nat Rev Nephrol (2009) 0.94
Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol (2009) 0.94
Congenital nephrotic syndrome responsive to angiotensin-converting enzyme inhibition. Pediatr Nephrol (2005) 0.94
Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 0.94
Obesity and kidney protection. J Nephropathol (2014) 0.93
The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry. Curr Cardiovasc Risk Rep (2011) 0.93
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 9.59
A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest (1972) 3.14
Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther (2012) 2.87
Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med (1995) 2.57
Uracil-DNA glycosylase (UNG)-deficient mice reveal a primary role of the enzyme during DNA replication. Mol Cell (2000) 2.54
Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia (2002) 2.32
A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord (2002) 2.29
Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest (1993) 2.16
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet (1994) 2.14
Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes (1998) 1.99
Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia (2011) 1.94
Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia (2002) 1.93
Long-term continuous glucose monitoring with microdialysis in ambulatory insulin-dependent diabetic patients. Lancet (1993) 1.85
Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med (2006) 1.84
Characterization of phosphoproteins from electrophoretic gels by nanoscale Fe(III) affinity chromatography with off-line mass spectrometry analysis. Proteomics (2001) 1.83
Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest (1997) 1.74
Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer (1998) 1.73
Catecholamine resistance in fat cells of women with upper-body obesity due to decreased expression of beta 2-adrenoceptors. Diabetologia (1994) 1.73
Feature-selective attention enhances color signals in early visual areas of the human brain. Proc Natl Acad Sci U S A (2006) 1.63
Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. J Immunol (1994) 1.60
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia (2004) 1.57
The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity. Diabetologia (2002) 1.53
Respiratory syncytial virus infection--risk factors for hospital admission: a case-control study. Acta Paediatr (2003) 1.53
A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res (2002) 1.50
Strong association between mitochondrial DNA copy number and lipogenesis in human white adipose tissue. Diabetologia (2007) 1.49
Mechanisms underlying regional differences in lipolysis in human adipose tissue. J Clin Invest (1989) 1.48
Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes (1983) 1.48
Deleterious effect of dithizone-DMSO staining on insulin secretion in rat and human pancreatic islets. Pancreas (1994) 1.45
Drug distribution studies with microdialysis. III: Extracellular concentration of caffeine in adipose tissue in man. Life Sci (1991) 1.44
Eosinophilia-myalgia syndrome in Germany: an epidemiologic review. Mayo Clin Proc (1994) 1.44
Self-monitoring of blood glucose in type I diabetic patients: comparison with continuous microdialysis measurements of glucose in subcutaneous adipose tissue during ordinary life conditions. Diabetes Care (1997) 1.42
No association of reported functional protein tyrosine phosphatase 1B 3' UTR gene polymorphism with features of the metabolic syndrome in a Swedish population. J Intern Med (2004) 1.41
Carbohydrate three-carbon metabolism of adipose tissue during surgery. Nutrition (1996) 1.39
Hepatic nuclear factor 1-alpha directs nucleosomal hyperacetylation to its tissue-specific transcriptional targets. Mol Cell Biol (2001) 1.39
Phenotypic and genotypic characterization of phenanthrene-degrading fluorescent Pseudomonas biovars. Appl Environ Microbiol (1996) 1.38
[Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II]. Dtsch Med Wochenschr (2000) 1.38
Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia (2010) 1.37
Regional differences in the control of lipolysis in human adipose tissue. Metabolism (1979) 1.35
Microdialysis measurement of the absolute glucose concentration in subcutaneous adipose tissue allowing glucose monitoring in diabetic patients. Diabetologia (1992) 1.34
Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia (2001) 1.33
Automatic luminometric kinetic assay of glycerol for lipolysis studies. Anal Biochem (1989) 1.31
Renal inulin clearance versus total plasma clearance of 51Cr-EDTA. Scand J Clin Lab Invest (1969) 1.31
Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest (1976) 1.31
A pathogenic role of visceral fat beta 3-adrenoceptors in obesity. J Clin Invest (1995) 1.30
Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the DETECT program. Curr Med Res Opin (2005) 1.29
Evidence for a functional beta 3-adrenoceptor in man. Br J Pharmacol (1993) 1.27
Effect of time interval between breast-conserving surgery and radiation therapy on ipsilateral breast recurrence. Int J Radiat Oncol Biol Phys (2000) 1.27
Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. J Lipid Res (1999) 1.25
Treatment of malignant pheochromocytoma. Horm Metab Res (2009) 1.25
Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid (2001) 1.23
Demonstration of an in vivo functional beta 3-adrenoceptor in man. J Clin Invest (1995) 1.22
Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest (1994) 1.22
Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab (1992) 1.21
Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol (2001) 1.21
Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis. Diabetologia (2003) 1.20
Postreceptor defects causing insulin resistance in normoinsulinemic non-insulin-dependent diabetes mellitus. Diabetes (1982) 1.20
Bayesian analysis of response to selection: a case study using litter size in Danish Yorkshire pigs. Genetics (2000) 1.19
Effects of insulin on adrenoceptor binding and the rate of catecholamine-induced lipolysis in isolated human fat cells. J Biol Chem (1988) 1.19
Eosinophil response to migrating Ascaris suum larvae in normal and congenitally thymus-less mice. Acta Pathol Microbiol Scand B Microbiol Immunol (1974) 1.19
Absolute concentrations of glycerol and lactate in human skeletal muscle, adipose tissue, and blood. Am J Physiol (1997) 1.19
Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett (1995) 1.17
Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab (1998) 1.17
Prospective and controlled studies of the actions of insulin and catecholamine in fat cells of obese women following weight reduction. Diabetologia (2005) 1.17
Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest (1995) 1.16
Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes (1997) 1.16
Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia (2004) 1.16
Regulation of lipolysis during the neonatal period. Importance of thyrotropin. J Clin Invest (1988) 1.16
Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest (1997) 1.16
Inuit health in Greenland: a population survey of life style and disease in Greenland and among Inuit living in Denmark. Int J Circumpolar Health (2003) 1.16
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia (2004) 1.14
Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4. Diabetologia (2008) 1.14
Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia (1998) 1.14
Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm Metab Res Suppl (1988) 1.13
Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia (2007) 1.13
Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol (2003) 1.13
Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care (2000) 1.12
Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem (1999) 1.12
Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome -- a randomized study (SYSDIET). J Intern Med (2013) 1.12
Increased adipose angiotensinogen gene expression in human obesity. Obes Res (2000) 1.11
Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol (1998) 1.11
Reduced hepatic insulin extraction in obesity: relationship with plasma insulin levels. J Clin Endocrinol Metab (1983) 1.10
Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care (1983) 1.10
Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord (2004) 1.09
Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. Int J Obes Relat Metab Disord (2001) 1.09
The antilipolytic effect of insulin in human adipose tissue in obesity, diabetes mellitus, hyperinsulinemia, and starvation. Metabolism (1981) 1.09
Properties and functions of human uracil-DNA glycosylase from the UNG gene. Prog Nucleic Acid Res Mol Biol (2001) 1.09
4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol (1999) 1.09
Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J Lipid Res (2000) 1.09
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia (2005) 1.09
Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer (2011) 1.09
The 1997 ADA diabetes diagnostic categories: impact on employees' annual medical examination. Diabet Med (1999) 1.08
Impairment and recovery of elementary cognitive function induced by hypoglycemia in type-1 diabetic patients and healthy controls. J Clin Endocrinol Metab (2000) 1.08
Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control. Diabetes Res Clin Pract (2006) 1.08
Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med (2007) 1.08
The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol (2009) 1.07
4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes (1998) 1.07
Tumour necrosis factor-alpha in human adipose tissue -- from signalling mechanisms to clinical implications. J Intern Med (2007) 1.06
Variation in adrenergic regulation of lipolysis between omental and subcutaneous adipocytes from obese and non-obese men. J Lipid Res (1997) 1.06